Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Recruiting 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Gastrointestinal 11Breast 5Gynecologic 3Thoracic 2CNS 2Sarcoma 1Plasma cell 1Head & Neck 1

Conditions

Carcinoma, Non-Small-Cell Lung 2

Interventions

Carboplatin 510Cisplatin 410Pemetrexed 400Radiotherapy 285Docetaxel 244Paclitaxel 227pembrolizumab 226Gemcitabine 198Drug Therapy 191Bevacizumab 190Erlotinib Hydrochloride 189Radiosurgery 177Nivolumab 168Etoposide 155durvalumab 154osimertinib 126atezolizumab 109Gefitinib 96Blood Specimen Collection 93Magnetic Resonance Spectroscopy 91Vinorelbine 90anlotinib 88Surgical Procedures, Operative 85Ipilimumab 62Immunotherapy 62Surveys and Questionnaires 60sintilimab 59Specimen Handling 59tislelizumab 58Irinotecan 57

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Combined Modality Therapy × Thoracic × Clear all
NCT07610616 2026-05-28

Study on the Mechanism of ADC Drug Evaluation Based on Immune Co-culture of Lung Cancer Organoids

Guangzhou Institute of Respiratory Disease

Recruiting
10 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04846452 2021-08-12

Sintilimab, Anlotinib Hydrochloride and Platinum-Containing Dual-Agent Chemotherapy in NSCLC

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Unknown
40 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡